The Japanese government on March 7 announced new NHI prices for the FY2025 drug price revision, effective April 1. With…
HOME > BUSINESS
BUSINESS
- Astellas to End License Agreement with US Venture Company for AD Treatments
October 20, 2014
- AMO Japan Appoints Shoko Suzuki of Coca-Cola Japan as New President
October 20, 2014
- Takeda, euglena Strike Comprehensive Collaboration Deal for Euglena-Containing Product Development
October 20, 2014
- Bayer AG Aims to Achieve Japan Sales of 300 Billion Yen by 2017
October 17, 2014
- Bayer HealthCare Signs Two-Year Collaborative Search Activity Agreement with Kyoto Univ.
October 17, 2014
- FDA Gives Priority Review Status to Lenvatinib, Rufinamide: Eisai
October 17, 2014
- Pfizer Japan Voluntarily Recalls Torisel Due to Microparticles in Diluent
October 17, 2014
- EPS to Take Full Control of EP-Mint in January
October 16, 2014
- Mochida Hooks Up with LG Life Sciences on Adalimumab Biosimilar
October 16, 2014
- Daiichi Sankyo Launches Tender Offer for US Biotech Ambit
October 16, 2014
- FDA OKs World’s 1st Oral Combination Drug for CINV: Helsinn, Eisai
October 16, 2014
- Astellas, Harvard Conduct Joint Research for Retinitis Pigmentosa
October 16, 2014
- Kyorin Licenses Uritos to R-Pharm of Russia
October 15, 2014
- Parexel CEO Hails Rise of Partnership-Based Outsourcing in Japan
October 14, 2014
- Fujifilm’s Overseas Subsidiaries Develop High-Performance Mammalian Expression Platform
October 14, 2014
- Velcade Approved in US for Treatment-Naïve Mantle Cell Lymphoma: Takeda
October 14, 2014
- GSK to Market Authorized Generics through Aspen Japan Unit
October 10, 2014
- Kowa Loses Trademark Suit against Meiji Seika Pharma
October 10, 2014
- Ethical Drug Sales Down 7.2% in August, Switch to Generics Accelerated: Crecon Report
October 10, 2014
- AZ’s US Subsidiary Obtains Exclusive Rights to Shionogi’s Biologic Research Program
October 9, 2014
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…